Orphan Drug Designation Granted to Glioblastoma Multiforme Therapy

Bexion Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to Saposin C, the active ingredient in BXQ-350 for the potential treatment of glioblastoma multiforme.

In pre-clinical studies, Bexion’s first-in-class biologic, BXQ-350 has shown promising results in selectively inducing cell death in the laboratory. BXQ-350 is a proprietary nanovesicle formulation of Saposin C (sphingolipid activator protein C, or SapC) and the phospholipid dioleoylphosphatidylserine (DOPS).

RELATED: Cancer Patients Rarely Demand Unnecessary Treatment, Tests

Previously, Bexion was awarded a Phase 2 Bridge Award (Small Business Innovation Research Grant) from the National Cancer Institute (NCI) to support the manufacture and clinical testing of BXQ-350.

For more information visit BexionPharma.com.